ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Advantages of PDE5i in the Management of Glucose Metabolism Disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 187305" data-attributes="member: 13851"><p><strong>Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: <span style="color: rgb(184, 49, 47)">A Clinical and Translational Issue </span></strong></p><p></p><p></p><p></p><p></p><p><em><span style="color: rgb(184, 49, 47)">Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. </span><span style="color: rgb(44, 130, 201)">Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, plays an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases.</span></em> <span style="color: rgb(44, 130, 201)"><em>In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. </em></span><span style="color: rgb(184, 49, 47)"><em>Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans. </em></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"></span></p><p><span style="color: rgb(184, 49, 47)"><strong>6.</strong></span><span style="color: rgb(0, 0, 0)"><strong> Conclusions </strong></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><em><strong>Besides their well-known effects on ED, different preclinical, and clinical studies on the use of PDE5 inhibitors for metabolic disease treatment have been conducted. Indeed, PDE5 enzymes are highly expressed in all insulin-sensitive tissues, such as endothelium, muscle, adipocytes, and hepatocytes. Moreover, PDE5i interferes with the NO/cGMP signaling, an important pathway that controls glucose metabolism regulation. Thus, by regulating NO/cGMP pathways, PDE5i administration could provide a good strategy to promote glucose uptake and may be a new pharmacological approach to treat metabolic diseases (Figure 2).</strong></em> </span><span style="color: rgb(44, 130, 201)"><strong><em>Given the safety record of these drugs, it is desirable to speculate on the use of PDE5 inhibition as a potential approach in the prevention of diet-induced IR and metabolic imbalances. Although different encouraging data are available, further in vivo and in vitro indications are mandatory. </em></strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 187305, member: 13851"] [B]Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: [COLOR=rgb(184, 49, 47)]A Clinical and Translational Issue [/COLOR][/B] [I][COLOR=rgb(184, 49, 47)]Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. [/COLOR][COLOR=rgb(44, 130, 201)]Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, plays an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases.[/COLOR][/I] [COLOR=rgb(44, 130, 201)][I]In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. [/I][/COLOR][COLOR=rgb(184, 49, 47)][I]Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans. [/I] [B]6.[/B][/COLOR][COLOR=rgb(0, 0, 0)][B] Conclusions [/B][/COLOR] [COLOR=rgb(184, 49, 47)][I][B]Besides their well-known effects on ED, different preclinical, and clinical studies on the use of PDE5 inhibitors for metabolic disease treatment have been conducted. Indeed, PDE5 enzymes are highly expressed in all insulin-sensitive tissues, such as endothelium, muscle, adipocytes, and hepatocytes. Moreover, PDE5i interferes with the NO/cGMP signaling, an important pathway that controls glucose metabolism regulation. Thus, by regulating NO/cGMP pathways, PDE5i administration could provide a good strategy to promote glucose uptake and may be a new pharmacological approach to treat metabolic diseases (Figure 2).[/B][/I] [/COLOR][COLOR=rgb(44, 130, 201)][B][I]Given the safety record of these drugs, it is desirable to speculate on the use of PDE5 inhibition as a potential approach in the prevention of diet-induced IR and metabolic imbalances. Although different encouraging data are available, further in vivo and in vitro indications are mandatory. [/I][/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Advantages of PDE5i in the Management of Glucose Metabolism Disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top